HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hb Bibba or alpha 2 136(H19)Leu-->Pro beta 2 in a Caucasian family from Alabama.

Abstract
Several members of a large Caucasian family who presented with a congenital Heinz body hemolytic anemia were found to be carriers of the unstable Hb Bibba or alpha 2 136(H19)Leu-->Pro beta 2. Identification by protein analysis was hampered by the instability of the variant which complicated its isolation from shipped blood samples. Moreover, the detection of the CTG-->CCG mutation at codon 136 of the alpha 2 gene required the substitution of dGTP by dITP during the DNA sequencing process to prevent the occurrence of secondary structures and compressions in the sequencing gel. The first Hb Bibba heterozygote, characterized in 1968 (1), is believed to be a member of this family. The clinical expression of the disease is surprisingly variable.
AuthorsJ T Prchal, B Adler, J B Wilson, E Baysal, W B Qin, T P Molchanova, D D Pobedimskaya, E G Kazanetz, T H Huisman
JournalHemoglobin (Hemoglobin) 1995 May-Jul Vol. 19 Issue 3-4 Pg. 151-64 ISSN: 0363-0269 [Print] England
PMID7558871 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Hemoglobins, Abnormal
  • Globins
  • hemoglobin Bibba
Topics
  • Alabama
  • Amino Acid Sequence
  • Anemia, Hemolytic, Congenital (blood, genetics)
  • Base Sequence
  • DNA Mutational Analysis
  • Electrophoresis, Polyacrylamide Gel
  • Female
  • Genetic Variation
  • Globins (genetics)
  • Heinz Bodies (ultrastructure)
  • Hemoglobins, Abnormal (chemistry, genetics)
  • Heterozygote
  • Humans
  • Male
  • Molecular Sequence Data
  • Pedigree
  • Point Mutation
  • White People (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: